Developer docs
API playgroundTry for free, no card

Search company profiles

Epic Sciences

Full company profile

uuid0000b1i

Namestring
Epic Sciences
Legal namestring
Epic Sciences
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Epic Sciences is a San Diego-based, privately held diagnostics company founded in 2008 that develops liquid biopsy solutions for oncology. Its flagship product, DefineMBC™, is a blood-based biopsy test designed to detect and characterize circulating tumor cells in metastatic breast cancer patients, providing a non-invasive alternative to surgical tissue biopsy for tumor analysis and treatment monitoring.

The company is built on a proprietary Multi-Omic Platform that combines single-cell sequencing with data analytics to enable comprehensive characterization of cancer from blood samples. This platform underpins both the DefineMBC clinical diagnostic and the company's pharmaceutical services offering, in which Epic Sciences partners with drug developers to support oncology clinical trials through patient stratification, biomarker discovery, and therapeutic monitoring. Over 700 patients have been tested through DefineMBC pilot programs.

Epic Sciences generates revenue through diagnostic testing services for healthcare providers (oncologists, cancer centers, hospital systems) and through subscription-style collaborations with pharmaceutical and biotech companies conducting oncology clinical trials. The company is in active commercial scaling mode following a $43 million Series F round in June 2022 and a $24 million Series G round in April 2023, with proceeds dedicated to expanding sales, marketing, and clinical evidence generation for DefineMBC. The company operates exclusively in the United States and employs 101–250 people.

Short descriptiontext

Epic Sciences is a private San Diego-based diagnostics company that has developed DefineMBC™, a blood-based liquid biopsy test for metastatic breast cancer, powered by a proprietary multi-omic single-cell sequencing platform serving oncology providers and pharmaceutical clinical trial sponsors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLa Jolla, United States
HQ citystring
La Jolla
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liquid biopsy diagnostics, cancer diagnostic tests, single-cell sequencing, precision oncology, companion diagnostics
Industry4 codes
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAJ
Reference & Esoteric Testing Laboratories
NAICS code3 codes
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Cancer Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Testing Services
TypeOne Time License
Description

Revenue generated from commercializing DefineMBC blood-based biopsy tests for metastatic breast cancer diagnosis and monitoring

dlvr.it
2Pharmaceutical Partnerships
TypeSubscription Recurring
Description

Collaborations with drug development companies for liquid biopsy solutions supporting oncology clinical trials

biospace.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Epic Sciences develops and commercializes blood-based liquid biopsy diagnostic tests for oncology applications. The company's flagship product, DefineMBC, is a multi-omic test designed to inform treatment decisions for patients with metastatic breast cancer by analyzing circulating tumor cells and cell-free DNA from a single blood sample.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Over 700 patients successfully tested during pilot programs
+1 more record
Product overview1 text field

Epic Sciences offers a diagnostics platform focused on liquid biopsy solutions for oncology. The core product is the DefineMBC™ blood-based biopsy test for metastatic breast cancer, powered by the company's Multi-Omic Platform that incorporates single-cell sequencing and advanced data analytics. The platform enables non-invasive cancer analysis from blood samples, supporting both clinical diagnostics and pharmaceutical drug development collaborations.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Guardant Health is a leading liquid biopsy company offering oncology blood tests including Guardant360 for tumor profiling and Guardant Reveal for MRD — directly competing with Epic Sciences in the oncology liquid biopsy market with similar single-cell and ctDNA-based approaches serving oncologists and pharmaceutical companies.

TypeDirect peer
Description

Natera offers Signatera, a tumor-informed MRD liquid biopsy test used for treatment monitoring in multiple solid tumor types including breast cancer, directly overlapping with Epic Sciences' DefineMBC in clinical use case, customer base (oncologists and pharma), and business model.

TypeBroad incumbent
Description

Foundation Medicine (acquired by Roche) provides comprehensive genomic profiling assays including FoundationOne Liquid CDx for blood-based tumor profiling. As a Roche-owned incumbent with broad pharma partnerships and established reimbursement, it represents a much larger competitor in the same oncology liquid biopsy space.

TypeBroad incumbent
Description

Exact Sciences is a publicly-traded cancer diagnostics company best known for Cologuard, with an expanding oncology portfolio including liquid biopsy tests. It serves similar oncology and primary care customer segments with a much broader commercial footprint and menu.

TypeDirect peer
Description

Personalis is a cancer genomics company developing liquid biopsy assays including NeXT Personal for MRD detection and tumor profiling. It competes directly with Epic Sciences in providing multi-omic, blood-based diagnostics for oncology treatment monitoring and pharma clinical trial support.

TypeDirect peer
Description

NeoGenomics is a specialized oncology testing services company offering a broad menu of cancer-focused lab tests including liquid biopsy assays. It serves oncologists, hospitals, and pharma clients with diagnostic testing — overlapping significantly with Epic Sciences' clinical testing business model.

TypeEmerging player
Description

Adaptive Biotechnologies applies immune sequencing and minimal residual disease detection in oncology (clonoSEQ for MRD in blood cancers). While primarily focused on hematologic malignancies, it represents an adjacent liquid biopsy / MRD player with similar pharma partnership and clinical diagnostic business models.

TypeDirect peer
Description

ANGLE plc has developed the Parsortix system for harvesting circulating tumor cells from blood, directly competing with Epic Sciences' CTC-based approach. Both companies focus on CTC analysis for oncology diagnostics and pharma applications, with overlapping customer bases and technology positioning.

TypeEmerging player
Description

Resolution Bioscience, acquired by Agilent in 2021, developed a liquid biopsy platform for oncology cfDNA analysis with pharma partnership focus — closely comparable to Epic Sciences' liquid biopsy platform and pharma services business, now operating within Agilent's broader diagnostics portfolio.

TypeBroad incumbent
Description

Bio-Techne provides reagents, instruments, and diagnostic tools used in oncology research and clinical diagnostics, including exosome-based and circulating biomarker products. While a much larger and broader life-sciences tools provider, it overlaps with Epic Sciences in enabling liquid biopsy and oncology diagnostic workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Epic Sciences

Cancer Diagnosticsepicsciences.com

Epic Sciences is a private San Diego-based diagnostics company that has developed DefineMBC™, a blood-based liquid biopsy test for metastatic breast cancer, powered by a proprietary multi-omic single-cell sequencing platform serving oncology providers and pharmaceutical clinical trial sponsors.

What Epic Sciences does

Epic Sciences is a San Diego-based, privately held diagnostics company founded in 2008 that develops liquid biopsy solutions for oncology. Its flagship product, DefineMBC™, is a blood-based biopsy test designed to detect and characterize circulating tumor cells in metastatic breast cancer patients, providing a non-invasive alternative to surgical tissue biopsy for tumor analysis and treatment monitoring.

The company is built on a proprietary Multi-Omic Platform that combines single-cell sequencing with data analytics to enable comprehensive characterization of cancer from blood samples. This platform underpins both the DefineMBC clinical diagnostic and the company's pharmaceutical services offering, in which Epic Sciences partners with drug developers to support oncology clinical trials through patient stratification, biomarker discovery, and therapeutic monitoring. Over 700 patients have been tested through DefineMBC pilot programs.

Epic Sciences generates revenue through diagnostic testing services for healthcare providers (oncologists, cancer centers, hospital systems) and through subscription-style collaborations with pharmaceutical and biotech companies conducting oncology clinical trials. The company is in active commercial scaling mode following a $43 million Series F round in June 2022 and a $24 million Series G round in April 2023, with proceeds dedicated to expanding sales, marketing, and clinical evidence generation for DefineMBC. The company operates exclusively in the United States and employs 101–250 people.

Epic Sciences firmographics

Firmographics
Name
Epic Sciences
Legal name
Epic Sciences
Website
https://epicsciences.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Epic Sciences is a private San Diego-based diagnostics company that has developed DefineMBC™, a blood-based liquid biopsy test for metastatic breast cancer, powered by a proprietary multi-omic single-cell sequencing platform serving oncology providers and pharmaceutical clinical trial sponsors.
Ownership category
akta.pro rank

Epic Sciences industry classification

Industry
Product category
Cancer Diagnostics
NAICS
Medical Laboratories (621511), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAJ
Reference & Esoteric Testing Laboratories

Keywords

  • Liquid biopsy diagnostics
  • Cancer diagnostic tests
  • Single-cell sequencing
  • Precision oncology
  • Companion diagnostics

Where Epic Sciences is headquartered

Location

Headquarters

HQ city
La Jolla
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Epic Sciences business model

Business model
GTM type
B2B
Offering type
Services

Revenue model

  1. Diagnostic Testing Services: Revenue generated from commercializing DefineMBC blood-based biopsy tests for metastatic breast cancer diagnosis and monitoring
  2. Pharmaceutical Partnerships: Collaborations with drug development companies for liquid biopsy solutions supporting oncology clinical trials

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Epic Sciences product offering

Product offering

Core offering

Epic Sciences develops and commercializes blood-based liquid biopsy diagnostic tests for oncology applications. The company's flagship product, DefineMBC, is a multi-omic test designed to inform treatment decisions for patients with metastatic breast cancer by analyzing circulating tumor cells and cell-free DNA from a single blood sample.

Product overview

Epic Sciences offers a diagnostics platform focused on liquid biopsy solutions for oncology. The core product is the DefineMBC™ blood-based biopsy test for metastatic breast cancer, powered by the company's Multi-Omic Platform that incorporates single-cell sequencing and advanced data analytics. The platform enables non-invasive cancer analysis from blood samples, supporting both clinical diagnostics and pharmaceutical drug development collaborations.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Over 700 patients successfully tested during pilot programs
  • +1 more outcomes

Companies that use Epic Sciences

Customer profile

Named customers1 record

Segments2 records

Epic Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Epic Sciences partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Epic Sciences competitors and assessment

Company assessment

Direct peers

  • Guardant Health: Guardant Health is a leading liquid biopsy company offering oncology blood tests including Guardant360 for tumor profiling and Guardant Reveal for MRD — directly competing with Epic Sciences in the oncology liquid biopsy market with similar single-cell and ctDNA-based approaches serving oncologists and pharmaceutical companies.
  • Natera: Natera offers Signatera, a tumor-informed MRD liquid biopsy test used for treatment monitoring in multiple solid tumor types including breast cancer, directly overlapping with Epic Sciences' DefineMBC in clinical use case, customer base (oncologists and pharma), and business model.
  • Personalis: Personalis is a cancer genomics company developing liquid biopsy assays including NeXT Personal for MRD detection and tumor profiling. It competes directly with Epic Sciences in providing multi-omic, blood-based diagnostics for oncology treatment monitoring and pharma clinical trial support.
  • NeoGenomics: NeoGenomics is a specialized oncology testing services company offering a broad menu of cancer-focused lab tests including liquid biopsy assays. It serves oncologists, hospitals, and pharma clients with diagnostic testing — overlapping significantly with Epic Sciences' clinical testing business model.
  • ANGLE plc: ANGLE plc has developed the Parsortix system for harvesting circulating tumor cells from blood, directly competing with Epic Sciences' CTC-based approach. Both companies focus on CTC analysis for oncology diagnostics and pharma applications, with overlapping customer bases and technology positioning.

Broad incumbents

  • Foundation Medicine: Foundation Medicine (acquired by Roche) provides comprehensive genomic profiling assays including FoundationOne Liquid CDx for blood-based tumor profiling. As a Roche-owned incumbent with broad pharma partnerships and established reimbursement, it represents a much larger competitor in the same oncology liquid biopsy space.
  • Exact Sciences: Exact Sciences is a publicly-traded cancer diagnostics company best known for Cologuard, with an expanding oncology portfolio including liquid biopsy tests. It serves similar oncology and primary care customer segments with a much broader commercial footprint and menu.
  • Bio-Techne: Bio-Techne provides reagents, instruments, and diagnostic tools used in oncology research and clinical diagnostics, including exosome-based and circulating biomarker products. While a much larger and broader life-sciences tools provider, it overlaps with Epic Sciences in enabling liquid biopsy and oncology diagnostic workflows.

Emerging players

  • Adaptive Biotechnologies: Adaptive Biotechnologies applies immune sequencing and minimal residual disease detection in oncology (clonoSEQ for MRD in blood cancers). While primarily focused on hematologic malignancies, it represents an adjacent liquid biopsy / MRD player with similar pharma partnership and clinical diagnostic business models.
  • Resolution Bioscience (Agilent): Resolution Bioscience, acquired by Agilent in 2021, developed a liquid biopsy platform for oncology cfDNA analysis with pharma partnership focus — closely comparable to Epic Sciences' liquid biopsy platform and pharma services business, now operating within Agilent's broader diagnostics portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Epic Sciences social profiles

Digital presence

Epic Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Epic Sciences leadership team

Management profile

Number of profiles

Epic Sciences funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Epic Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epic Sciences

What does Epic Sciences do?

Epic Sciences develops and commercializes blood-based liquid biopsy diagnostic tests for oncology applications. The company's flagship product, DefineMBC, is a multi-omic test designed to inform treatment decisions for patients with metastatic breast cancer by analyzing circulating tumor cells and cell-free DNA from a single blood sample.

Is Epic Sciences a public or private company?

Epic Sciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Epic Sciences founded?

Epic Sciences was founded in 2008. It employs 11 to 50 people.

Where is Epic Sciences based?

Epic Sciences is headquartered in La Jolla, United States, in the North America region.

How does Epic Sciences make money?

Two revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are pharmaceutical Partnerships.

Who are Epic Sciences's main competitors?

Direct peers on record are Guardant Health, Natera, Personalis, NeoGenomics and ANGLE plc. Broad incumbents are Foundation Medicine, Exact Sciences and Bio-Techne. Emerging players are Adaptive Biotechnologies and Resolution Bioscience (Agilent).

Does Epic Sciences have an API?

No public API is recorded for Epic Sciences.

What industry is Epic Sciences in?

Epic Sciences's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Disease Progression Diagnostics Company Epic Sciences Raises $24 MillionEpic Sciences raised $24 million in a Series G round, bringing total funding to $67 million in 12 months. The funds will support commercializing its DefineMBC blood-based biopsy tests for metastatic breast cancer, which have been delivered to 700 patients.dlvr.itDisease Progression Diagnostics Company Epic Sciences Raises $24 MillionEpic Sciences secured $24 million in Series G funding, bringing its total raised over the last 12 months to $67 million. The capital will be used to build commercial infrastructure and expand market-facing departments for DefineMBC, a blood-based diagnostic test for metastatic breast cancer. The investment was co-led by Deerfield Management and Arsenal Capital Partners with participation from existing shareholders including Labcorp.socaltech.comEpic Sciences Finds $24MSan Diego-based Epic Sciences secured $24 million in Series G funding co-led by Deerfield Management and Arsenal Capital Partners. The company intends to use the capital to support the commercial launch of its blood-based biopsy test for patients with metastatic breast cancer.FinSMEsEpic Sciences Raises $24M in Series G FinancingEpic Sciences raised $24 million in Series G funding, bringing its total capitalization to $67 million, with the round led by Deerfield Management and Arsenal Capital Partners. The company intends to use the proceeds to build commercial infrastructure for its DefineMBC tests and develop additional outcomes data. This investment supports Epic Sciences' efforts to expand sales, marketing, and medical affairs departments for its liquid biopsy diagnostics.Business Wire BlogEpic Sciences Raises $24M in Series G Financing to Continue Funding Commercialization of DefineMBCEpic Sciences has completed a $24 million Series G financing round, co-led by Deerfield Management and Arsenal Capital Partners, bringing its total raised capital to $67 million over the last twelve months. The company intends to use these funds to establish commercial infrastructure for DefineMBC, a comprehensive blood-based biopsy test for metastatic breast cancer. This investment supports the expansion of sales, marketing, and payer relations departments following positive feedback from an initial clinical experience program involving 700 patients.Venture Capital Access OnlineEpic Sciences Raises $24M in Series G Financing to Continue Funding Commercialization of DefineMBCEpic Sciences completed a $24 million Series G financing round, bringing its total raised capital to $67 million over the last twelve months. The company will utilize these funds to establish commercial infrastructure and expand market-facing departments for the launch of its DefineMBC diagnostic test for metastatic breast cancer. The investment was co-led by Deerfield Management and Arsenal Capital Partners with participation from existing shareholders including Labcorp.BioSpaceEpic Sciences Raises $24M in Series G Financing to Continue Funding Commercialization of DefineMBCEpic Sciences, Inc. has raised $24 million in a Series G financing round to fund the commercialization of its DefineMBC tests for metastatic breast cancer. This funding, combined with a previous $43 million from Series F, brings the total to $67 million raised over the past twelve months. The investment aims to enhance the company's commercial infrastructure and expand market-facing departments to support the launch of DefineMBC.VC News DailyEpic Sciences Raises $24M in Series GEpic Sciences has completed a $24 million Series G financing round, co-led by Deerfield Management and Arsenal Capital Partners. The company intends to use the capital to fund the commercial infrastructure for its DefineMBC blood-based biopsy tests for metastatic breast cancer patients.PR NewswireEPIC SCIENCES EXPANDS EXECUTIVE TEAM AND WELCOMES NEW CHIEF FINANCIAL OFFICER IN PREPARATION FOR RAPID GROWTHEpic Sciences, Inc., a privately held diagnostics company based in San Diego, announced the appointment of William J. Kullback as Chief Financial Officer, with Joel S. Smith transitioning to continue in his other executive roles as General Counsel, Chief Compliance Officer, and Executive Vice President of Corporate Development. The company cited its recent launch of DefineMBC, a multi-analyte blood test for metastatic breast cancer, and expectations for significant growth in operations, headcount, and revenue in 2023 as rationale for the executive expansion. Kullback brings 27 years of CFO experience, most recently from BioLegend, Inc., where he led the company's sale to PerkinElmer for $5.25 billion.BioSpaceEpic Sciences Expands Executive Team and Welcomes New Chief Financial Officer in Preparation for Rapid GrowthEpic Sciences appointed William J. Kullback as Chief Financial Officer, with Joel S. Smith continuing in other executive roles. Kullback previously served as CFO of BioLegend, which was acquired by PerkinElmer for $5.25 billion. The appointment supports Epic's growth following the launch of its DefineMBC blood test.